axicabtagene ciloleucel,polatuzumab vedotin,tafasitamab,loncastuximab
daiichi sankyo,gilead,roche
['axicel', 'axi-cel', ' cam ', 'dlbcl', 'cel sci']
#ash22 axicel compared to cit in scholar 1 pts &gt;65, cr rate 58% vs. 16%. cart cell therapy clearly better however, the control arm treatment was prior to availability of pola, tafa, lonca and bite which could change the outcomes of similar analysis with current treatments ! 
MD